Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
Recruiting
Phase 4
Interventional Study
Subarachnoid Hemorrhage, Aneurysmal
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 85
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 20 (estimated)
- Sponsor
- Aaron Cook · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs were chosen as the target population because they frequently require prolonged admission to the intensive care unit and drainage of CSF in order to prevent hydrocephalus. The estimated sample size is 2…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult aged 18-85 years
* Actively draining ventriculostomy
Exclusion Criteria:
* history of hypersensitivity to telavancin or similar agents
* reduced renal function (estimated creatinine clearance \< 50/ml) at the time of consent
* severe anemia (hemoglobin \< 7gm/dl)
* vul…
Contacts